Market Research Logo

Prefilled Syringes Market (4th Edition), 2016 - 2026

Prefilled Syringes Market (4th Edition), 2016 - 2026

Injectable drug delivery systems have traversed a long way from conventional syringes with vials to prefilled syringes, auto-injectors, pen injectors and needle free systems. These modern devices have become preferred devices for parenteral administration of drugs. Specifically, the demand for prefilled syringes has been rising strongly over the past several years. A growing number of healthcare facilities are now adopting this format for delivering drugs. The popularity of prefilled syringes is not limited to healthcare settings; self-injecting patients looking for easier and safer methods also prefer using prefilled syringes for drug administration in home settings. The rise in parenteral drugs, especially biologics for the treatment of diseases and chronic conditions, such as multiple sclerosis and rheumatoid arthritis, has forced drug and packaging manufacturers to seek more sophisticated container closure and drug delivery systems. Responding to this increasing preference, pharmaceutical companies are now packaging a number of their injectable drugs and vaccines in prefilled syringe format. Over 100 injectable drug products are available in prefilled syringes and a rising number of pipeline drugs are targeted to be delivered by this method.

The origins of prefilled syringes can be traced back to the early 1980s when Sanofi and Rhone Poulenc-Rorer (Sanofi-Aventis) introduced them as drug delivery devices for heparins in Europe. They have been around for more than three decades now and are used for administration of all major classes of therapeutics, including vaccines, anticoagulants, anti-arthritic drugs and anti-anemic drugs. Prefilled syringes have improved significantly over the years. Manufacturers have recently developed multi-chamber syringes for use with lyophilized drugs. Such syringes are also being integrated with advanced injection devices, such as autoinjectors and pen injectors. In addition, prefilled diluent syringes and flush syringes are already quite popular. With more than 60% of candidate drugs / therapies in the clinical pipeline being biologics that usually require parenteral administration, the adoption of prefilled syringes is anticipated to further increase in the mid-long term.

SCOPE OF THE REPORT
The ‘Prefilled Syringes Market (4th edition), 2016-2026’ report provides a comprehensive analysis of the current state of prefilled syringes market and the likely future evolution of these devices over the next decade. Starting with an overview on prefilled syringes, the report elaborates on the development and manufacturing of prefilled syringes. It also includes information on needlestick injuries and provides an overview of the safety laws and legislations related to prefilled syringes across the major markets in the world.

Some of the key objectives of the report were to enumerate the various prefilled syringe systems that are available in the market, identify the drugs that are available in such dosage forms and estimate their corresponding market potential across different geographical regions. Specifically, the report includes insights on:
 The current state of the market with respect to key players, targeted disease indications and the therapeutic classes of drugs that are available in the form of prefilled syringes, including a brief overview of biologics and biosimilars that are considered to be one of the primary growth drivers of this market.
 The key drugs that are available in prefilled syringes; this has been presented in the form of detailed case studies.
 The regulatory landscape in different countries, including the guidelines related to the grant of a marketing authorization for drugs in prefilled syringes.
 The candidates that are likely to be tried for delivery via prefilled syringes in the future. It is worth highlighting that the candidates were chosen based on various parameters, such as their current route of administration, targeted indication and dosage frequency.
 The key prefilled syringe and component manufacturers based in different geographies.
 Product competitiveness and supplier power (in the form of 2 X 2 matrices) across the growing landscape of glass and plastic prefilled syringes.
 Specialty syringes, which include prefilled flush syringes, prefilled diluent systems and contrast agents in prefilled syringes.
 The contract manufacturing organizations providing fill / finish services related to prefilled syringes.
 Future growth opportunities that are likely to drive the market in the short and long terms.

The study also features a detailed analysis of the existing market size and the potential future growth opportunities of these drug delivery devices across different classes of therapeutics. The analysis includes volumetric (number of units of prefilled syringes) and financial (future market size) projections of the market’s evolution over the next ten years (2016-2026). We have provided insights on the regional evolution of the prefilled syringes market covering North America, Europe (UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East). In addition, we have provided the likely evolution distributed by the type of material (glass and plastic), and nature of molecules (vaccines, biosynthetic insulins, synthetic pentasaccharides, monoclonal antibodies, small molecules). The forecast takes into account the impending price variations that are likely to emerge in the mid-long term as a result of growing adoption and increased competition. In order to account for the uncertainties associated with drug development and production, we have forecasted three different market scenarios, depicting conservative, base and optimistic tracks of the industry’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with experts in this field. These included contributions from Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical Services), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), and Rondald Wheet (Chief Executive Officer, Revolutions Medical). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. Currently, more than 100 drugs and vaccines are available in prefilled syringes across different therapeutic classes. Humira®, Enbrel®, Copaxone®, Lovenox®, Rebif® and Pegasys® are examples of blockbuster drugs that are being extensively administered via prefilled syringes. In addition, over 65 drugs in prefilled syringe format are in clinical development for the treatment of number of indications such as rheumatoid arthritis and multiple sclerosis.
2. The rise of biologics has emerged as a major growth driver. Additionally, a number of biologics are getting off patent in the coming few years. Biosimilar developers will be competing for the same drug and, in such situations, use of prefilled syringes as a mode of administration can act as a key differentiator. The market’s evolution in the long-term will be fueled by pipeline drugs, technological advances and the rising adoption in developing markets. Moreover, integration of prefilled syringes with advanced delivery systems such as pen and autoinjectors will aid in gaining wider adoption.
3. The development and launch of dual / multi-chambered syringes and prefilled diluent syringes has enabled easier and faster delivery of lyophilized drugs. Novel lubrication technologies such as TriboFilm Research’s TriboGlide® and Becton Dickinson’s XSi™ coating technologies have been introduced to overcome the problems associated with the use of silicone oil. Additionally, the design and availability of silicone-free and tungsten-free syringes is making them more suitable for use with sensitive drugs such as biologics.
4. The current market is highly consolidated and is dominated by a handful of key manufacturers such as Becton Dickinson, Gerresheimer, SCHOTT, and Nuova Ompi. Other key players include West Pharmaceutical Services and Vetter Pharma; these players have already driven some novel devices and technologies in the market and are likely to foster more innovation.
5. Many regional players have recently surfaced. Specifically in China, which has a large home consumer market, domestic players have an installed annual production capacity of as high as 150 million units; Shandong Weigao Group Medical Polymer Company, Shandong Zibo Minkang Pharmaceutical Packing, and Shandong Pharmaceutical Glass are well-known players. In Japan, Arte Corporation, Nipro Corporation, Taisei Kako and Terumo Corporation are known manufacturers of prefilled syringes; similarly, Roselabs Group, an India based manufacturer has invested heavily in this area.
6. Aseptic filling of sterile drugs into prefilled syringes is one of the most crucial steps in pharmaceutical production. During the course of our study, we identified more than 45 contract manufacturing organizations, which provide fill and finish services for prefilled syringes. Majority (~70%) of the fill and finish service providers are based in North America and Europe. Prominent players in these regions include Biopharma Solutions, Catalent, Pfizer CentreOne, Rovi CM and Boehringer Ingelheim BioXcellence. Some well-known fill and finish service providers based in emerging markets include Cipla BioTec, DM Bio, Genovior Biotech and The Birgi Mefar Group.
7. We anticipate the global prefilled syringe market to grow at an annualized rate of 3.9% between 2016 and 2026. The majority share of the prefilled syringes market is currently divided between North America (35%) and the EU (45%). We believe that the prefilled syringes markets in Asia, Latin America, the Middle East and Africa are likely to grow at faster rate than those of the more developed regions.

1.1. RESEARCH METHODOLOGY
Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

1.2. CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured in our research and offers a high level view on where the market for prefilled syringes is headed in the mid-long term.

Chapter 3 provides a general overview of prefilled syringes, including details on their origin, required components (barrel, lock adapter, lubricant, needle, needle shield, plunger rod / piston, plunger stopper and tip cap) and manufacturing material (glass and plastic) . The chapter outlines the various types of prefilled syringe systems that are available in the market and provides details on the companies that manufacture such products. It also includes a discussion on the technological advances that have taken place in the recent past.

Chapter 4 highlights the growing concerns associated with needlestick injuries and the various legislative steps that have been taken to prevent them. These include installing various safety features in modern versions of prefilled syringes. In addition, the chapter provides information on some of the safety systems, including both add-on devices and device integrated features, and the companies involved in developing and manufacturing such solutions.

Chapter 5 presents information on the regulatory environment related to the grant of marketing authorizations for combination products across different countries. It highlights the role of regulatory bodies in the approval of prefilled syringes in North America, Europe, Latin America, Asia Pacific and the Middle East.

Chapter 6 features a detailed discussion on the key growth drivers of the prefilled syringes market. It also describes the rise in the number of chronic diseases, the growing trend of self-injection, changing patient demographics, and the emergence of biologics / biosimilars.

Chapter 7 provides details of the various products available in the form of prefilled syringes, primarily focusing on injectable drugs and vaccines. The chapter includes case studies of some of the marketed drugs available as prefilled syringes, such as Humira®, Enbrel®, Copaxone®, Lovenox® and Abilify Maintena®. We have also captured details on the molecules that are under clinical development as prefilled syringes. The chapter features a grid analysis, representing the distribution of pipeline drugs across different therapeutic areas and different stages of clinical development. Additionally, the chapter outlines major therapeutic drug classes that are available as prefilled syringes. For each therapeutic class, we have identified the drugs that are already available in prefilled syringes, their estimated patent expiry dates and corresponding generics / biosimilars that are under development.

Chapter 8 presents a list of drug candidates (marketed / pipeline) that are likely to be tried for delivery via prefilled syringes in the future. This list is based on insights gathered on the respective routes of administration of these candidates, the nature of the indication they are prescribed for, dosage frequency and annual sales (in case of marketed drugs).

Chapter 9 provides detailed profiles of some of the key manufacturers of prefilled syringes based in different geographies. Each profile includes a brief overview of the company, its financial information, product portfolio, technology platforms, recent facility expansions and / or acquisitions, and a comprehensive future outlook. The companies that have been included in this section include Aguettant, Becton Dickinson, Gerresheimer, Nipro Corporation, Nuova Ompi, SCHOTT, Terumo Corporation, Unilife, Vetter Pharma, Weigao Group Pharmaceutical Packaging Products Company and West Pharmaceutical Services. In addition, we have included brief profiles of some of the key prefilled syringe manufacturers that are based in emerging markets. The chapter also presents 2 X 2 matrix representations, comparing product competitiveness and supplier power of both glass and plastic prefilled syringes.

Chapter 10 provides insights on the various prefilled syringe component manufacturers along with details of their respective product portfolios. The key players covered in this section include Aptar Stelmi, Datwyler and West Pharmaceutical Services.

Chapter 11 provides information on fill and finish activities and the processes and technologies associated with them. The chapter highlights the importance of aseptic fill and finish operations, and features a discussion on future trends in this segment. It also includes detailed profiles of the global players that are engaged in this segment of the industry.

Chapter 12 features information on specialty syringes, namely prefilled flush syringes, prefilled diluent systems and contrast agents that are supplied in prefilled syringes. For each type of specialty syringe, we have provided a brief overview and presented details such as the different products that are available in the market and their advantages.

Chapter 13 offers a comprehensive perspective on how the prefilled syringe market is likely to evolve over the next ten years. Based on data collected through secondary research and insights from primary research, we adopted a top-down approach in order to estimate the future size of the market, both in terms of volume (number of units) and value (in USD billion). We have projected the market’s evolution North America, Europe (UK, France, Italy, Spain, Germany and the rest of Europe), Latin America (Brazil, Mexico, Argentina and the rest of Latin America), Asia Pacific (Japan, China, India, South Korea and the rest of Asia Pacific), and the Middle East and Africa (Saudi Arabia, UAE, Africa and the rest of the Middle East). In addition, we have looked at the market’s evolution by the type of material (glass and plastic) used and the nature of the product contained within the syringe (vaccines, biosynthetic insulins, synthetic pentasaccharides, monoclonal antibodies, small molecules and others). The analysis presents insightful 2 X 2 matrices based on Market Share and Market Attractiveness derived from the current and likely future state of the market.

Chapter 14 presents a list of autoinjectors that utilize prefilled syringes as their primary containers. In this chapter, we have included profiles of manufacturers of such autoinjectors, featuring an overview of the company and respective product portfolios. The key players that have been covered in this section include Bespak, DALI Medical Devices, Elcam Medical, Nuance Owen Mumford, SHL Group, Union Medico and Ypsomed Delivery Systems.

Chapter 15 discusses the recent technological developments in this domain and their applications. The chapter provides details on the advances in design technology and manufacturing of prefilled syringes that have enabled pharmaceutical companies to market lyophilized drugs in dual / multi chambered systems. The chapter highlights the advances related to novel lubrication and sterilization technologies as well.

Chapter 16 provides a comprehensive SWOT analysis of the prefilled syringes market. The chapter presents strategic insights on major factors that have contributed to the growth of the market, while highlighting the weaknesses and threats that are likely to have an impact on its future.

Chapter 17 summarizes the overall report. In this chapter, we have provided a recap of the key takeaways and expressed our independent opinion, based on the research and analysis described in previous chapters, on how the market is likely to fare in the shot and long terms.

Chapter 18 is a collection of interview transcripts of our discussions with some of the key players in this industry. In this chapter, we have presented the details of our conversations with Kevin Cancelliere and Tibor Hlobik (Marketing Directors, West Pharmaceutical Services), Kirti Maheshwari (Chief Technical Officer, Intas Pharmaceuticals), Matthew Young (Founder and Chief Technology Officer, Oval Medical Technologies), and Rondald Wheet (Chief Executive Officer, Revolutions Medical).

Chapters 19 and 20 are appendices, which provide tabulated data of all the charts and the list of companies that are mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies have been mentioned in the report.
1. 3SBio
2. Abbott
3. AbbVie Biotherapeutics
4. AbbVie Contract Manufacturing
5. Ablynx
6. Acceleron Pharma
7. Accord Healthcare
8. AC Immune
9. Activa Brand Products
10. Adamis Pharmaceuticals Corporation
11. Advanced Medical Systems
12. AET BioTech
13. Aeras
14. Agila Biotech
15. Aguettant
16. AJ Biologics
17. Ajinomoto Althea
18. Akcea Therapeutics
19. Akorn
20. Aldagen
21. Alkermes
22. Alteogen
23. Adocia
24. Alchemia
25. Alder BioPharmaceuticals
26. Alfamatic
27. Allergan
28. Allergy Therapeutics
29. Allozyne
30. Alkermes
31. Almirall
32. Alvogen
33. AMEGA Biotech
34. Amgen
35. Amphastar Pharmaceuticals
36. AnGes
37. Antares Pharma
38. Anthera Pharmaceuticals
39. AOP Orphan Pharmaceuticals
40. Apellis Pharmaceuticals
41. APL Pharma
42. Aptar Stelmi
43. Apobiologix
44. Apotex
45. Aquabiliti
46. Araim Pharmaceuticals
47. Argenx
48. Ariston
49. Arte Corporation
50. AryoGen
51. Aspen Group
52. Astellas Pharma
53. AstraZeneca
54. Aurum Pharmaceuticals
55. Avesthagen
56. AXXO
57. Bahrain Pharma
58. Bang and Olufsen
59. BASF Bioresearch Corporation
60. Bavarian Nordic
61. Baxter
62. Bayer Healthcare
63. B. Braun Medical
64. Beacon Pharmaceuticals
65. Becton Dickinson
66. Bespak
67. Bharat Serums & Vaccines
68. BIOCAD
69. Biocon
70. BioConnection
71. Bio Farma
72. Biodel
73. Bio Elpida
74. BioGenomics
75. BioIncept
76. Bioject Medical Technologies
77. BioMarin Pharmaceutical
78. Bioneer
79. BioPharma Solutions
80. Biosidus
81. Biotechpharma
82. Biotech Visioncare
83. Bioviz Technologies
84. BioXpress Therapeutics
85. Blausiegel
86. Blau Farmacêutica
87. Boehringer Ingelheim BioXcellence
88. Bone Therapeutics
89. Boryung Pharmaceutical
90. Bracco Diagnostics
91. Braeburn Pharmaceuticals
92. BrainStorm Cell Therapeutics
93. Bristol Myers Squibb
94. Bryllan
95. Buender Glas
96. Cadila Healthcare
97. Cambridge Antibody Technology
98. Cambridge Consultants
99. Camurus
100. Canyon Pharmaceuticals
101. Capricor Therapeutics
102. Cardinal Health
103. Central Admixture Pharmacy Services
104. Catalent Pharma Solutions
105. CCM Pharmaceuticals
106. Celgene
107. Cellofarm
108. Celltrion
109. Cenexi
110. Chandra Bhagat Pharma
111. Chugai Pharmaceutical
112. CinnaGen
113. Cipla
114. Cipla BioTec
115. Cobra Biologics
116. Coherus Biosciences
117. Consort Medical
118. Cook Pharmica
119. Corden Pharma
120. Covidien
121. CP Guojian Pharmaceutical
122. CROSSJECT
123. Cytheris
124. CytoDyn
125. Cytori Therapeutics
126. Credence MedSystems
127. Crealta Pharmaceuticals
128. CSL Biotherapies
129. Daewoong Pharmaceutical
130. Daicel Corporation
131. Daiichi Sankyo
132. Daikyo Seiko
133. DALI Medical Devices
134. Datwyler
135. Dermira
136. Diasome Pharmaceuticals
137. Diamyd Medical
138. DM Bio
139. Dong-A Pharmaceutical
140. Dr. Lazar Laboratorio
141. Dr. Reddy's Laboratories
142. Dynavax Technologies Corporation
143. Eisai
144. Elan Corporation
145. Elcam Medical
146. Eli Lilly
147. Emcure Pharmaceuticals
148. EMD Serono
149. Emergent BioSolutions
150. Enzon Pharmaceuticals
151. Eternity Healthcare
152. European Medical Contract Manufacturing
153. Eurofarma
154. Evans Enterprises
155. EVER Pharma
156. Excelsior Medical
157. Exsulin
158. Eyetech
159. Farmabion Del Ecuador
160. Ferring Pharmaceuticals
161. Finox Biotech
162. Flamel Technologies
163. Fresenius Kabi
164. Fujifilm Kyowa Kirin Biologics
165. Future Injection Technologies
166. Gan & Lee Pharmaceutical
167. Gedeon Richter
168. GE Healthcare
169. Genentech
170. GeneOne Life Sciences
171. Gene Techno Science
172. Genovior Biotech
173. Generon (Shanghai) Corporation
174. Genocea Biosciences
175. Genzyme Corporation
176. GeoVax
177. Gerresheimer
178. GeroPharm
179. Gerot Lannach Pharma
180. Gilead Sciences
181. Gland Pharma
182. GlaxoSmithKline
183. GlobeImmune
184. Globe Medical Tech
185. Green Cross Corporation
186. Guerbet
187. Halozyme Therapeutics
188. HanAll Biopharma
189. Hanmi Pharmaceutical
190. Hanwha Chemical
191. Harvest Moon Pharmaceuticals
192. Haselmeier
193. Health for personal care corporation
194. Helocyte
195. Helvoet Pharmaceutical
196. Hemispherx Bioscience
197. Heron Therapeutics
198. Hikma Pharmaceuticals
199. Hospira
200. Horizon Pharma
201. Hyaluron Contract Manufacturing
202. Ichor Medical Systems
203. ID Biomedical Corporation of Quebec
204. Idera Pharmaceutical
205. Il-Yang Pharm
206. Immunex Corporation
207. Immunomedics
208. Immune Response BioPharma
209. Incepta Pharmaceuticals
210. Indivior
211. Infusive Technologies
212. Injex
213. Inovio Pharmaceuticals
214. Innovate UK
215. Intas Pharmaceuticals
216. Intarcia Therapeutics
217. Integrated BioTherapeutics
218. Integrity Bio
219. Ionis Pharmaceuticals
220. Ipsen
221. Italfarmaco
222. IVEK Corporation
223. Johnson & Johnson
224. J.O. Pharma
225. JSR Corporation
226. JCR Pharmaceuticals
227. JMS
228. JN-International Medical Corporation
229. Juventas Therapeutics
230. Kaleo
231. Kastle Therapeutics
232. Kendall
233. Kineta
234. Kitasato Daiichi Sankyo Vaccine
235. Kyowa Hakko Kirin
236. Laboratorios SALVAT
237. Landec Corporation
238. Landsteiner Laboratories
239. LEO Pharma
240. LG Life Sciences
241. Liebmann Group
242. Lifecore Biomedical
243. Lundbeck
244. Lupin Pharmaceuticals
245. LyoGo
246. Mada Equipment
247. Mallinckrodt
248. Marathon Pharmaceuticals
249. Maruishi Pharmaceutical
250. Medac Pharma
251. Medefil
252. Medex
253. Medicago
254. MedicalChain International Corporation
255. Medical Glass
256. MedImmune
257. Medimop Medical Projects
258. MedPro Safety Products
259. Medtronic
260. MedXL
261. Meiji Seika Pharma
262. Merck
263. Meridian Medical Technologies
264. Merz Pharma
265. MGlas
266. Minapharm Pharmaceuticals
267. Mitsubishi Tanabe
268. Mitsui Chemicals
269. Mitsubishi Gas Chemical
270. MJ Biopharm
271. Mochida Pharmaceuticals
272. Momenta Pharmaceuticals
273. Mycenax Biotech
274. Mylan Institutional
275. Nanogen Biopharmaceutical
276. Nanotherapeutics
277. NATCO Pharma
278. National Medical Products
279. Nektar Therapeutics
280. Nemera
281. Neon Laboratories
282. Neutral Glass & Allied industries
283. Nippon Organon
284. Nipro Corporation
285. Nora Therapeutics
286. Novartis
287. Novalek Pharmaceuticals
288. Nova Laboratories
289. NovaDigm Therapeutics
290. Novavax
291. Novo Nordisk
292. Noxilizer
293. NPS Pharmaceuticals
294. Nuance Designs
295. Nuova Ompi
296. Nuron Biotech
297. Nurse Assist
298. Okairos
299. Omnikron Group
300. Oncobiologics
301. Ono Pharmaceutical
302. Opexa Therapeutics
303. OPKO Biologics
304. Optimum Medical
305. OrbiMed
306. Otsuka Holdings
307. Oval Medical Technologies
308. Owen Mumford
309. PA Consulting
310. Palatin Technologies
311. PANPHARMA
312. Paras Biopharmaceuticals
313. Pars No Tarkib
314. PenJect
315. Pfenex
316. Pfizer
317. Pfizer CentreOne
318. PharmaEssentia Corporation
319. Pharmicell
320. Pharmathen
321. PhaseBio Pharmaceuticals
322. PiSA Farmaceutica
323. Plas-Tech Engineering
324. Pluristem Therapeutics
325. Polpharma
326. Polyplastics
327. PROBIOMED
328. Profectus BioSciences
329. ProJect Pharmaceutics
330. Protalix BioTherapeutics
331. Protein Sciences Corporation
332. PT Bio Farma
333. PYRAMID Laboratories
334. Radius Health
335. Ranbaxy Laboratories
336. Regeneron Pharmaceuticals
337. Reliance Life Sciences
338. REMD Biotherapeutics
339. Retractable Technologies
340. Revolutions Medical Corporation
341. Rexam Pharma
342. Rhône Poulenc-Rorer
343. Rheim Minapharm
344. Rhythm Pharmaceuticals
345. Rompharm Company
346. Roselabs Bioscience
347. Rovi CM
348. SafeShot Technologies
349. Safety Syringes
350. Samsung Bioepsis
351. Sandoz
352. Sanofi Aventis
353. Sanofi Pasteur
354. Santarus
355. Schering-Plough
356. Schreiner MediPharm
357. SCHOTT
358. SHOTT KAISHA
359. Sciele Pharma
360. Seqirus
361. Shandong Pharmaceutical Glass
362. Shandong Weigao Group Medical Polymer Company
363. Shandong Zibo Minkang Pharmaceutical Packing
364. Shanghai Celgen Bio-Pharmaceutical
365. Shantha Biotech
366. Shin Yan Sheno Precision Industrial
367. Shire
368. SHL Medical
369. SiO2 Medical Products
370. Sobi
371. Soligenix
372. Solvay Pharmaceuticals
373. SOVEREIGN PHARMA
374. Spectrum Pharmaceuticals
375. STADA Arzneimittel
376. Stevanato Group
377. Stiefel
378. Strides
379. Sumagen
380. Sun Pharmaceutical Industries
381. Sunshine Health Products
382. Suzuken
383. Swissfillon
384. TaiMed Biologics
385. Taisei Kako
386. Taiyo Yakuhin
387. Taj Pharmaceuticals
388. Takeda Pharmaceutical
389. Talecris Biotherapeutics
390. Techno Pharm
391. Techdow Pharmaceuticals
392. Teijin Pharma
393. Terumo Corporation
394. Teva Pharmaceuticals
395. The Birgi Mefar Group
396. The Medical House
397. The Medicines Company
398. Therapure Biopharma
399. The Tech Group
400. Ticona
401. Tip-Top
402. TOLMAR
403. TriboFilm Research
404. Triveni Polymers
405. Troikaa Pharmaceuticals
406. TSH Biopharm Corporation
407. Tyfill Pharmapack
408. UCB
409. Unicep
410. Unilife Corporation
411. Unimed del Perú
412. Union Medico
413. United Neuroscience
414. United Therapeutics
415. U.S. Medical Instruments
416. Valeant Pharmaceutical International
417. Valeritas
418. Vedat
419. Vaneva
420. VaxInnate
421. Versartis
422. Vetter Pharma
423. ViaCyte
424. Vical
425. Vitaeris
426. Virchow Biotech
427. Viropro
428. ViroMed
429. Watson Pharma
430. WestCon Medical Industries
431. West Pharmaceutical Services
432. Weigao Group Pharmaceutical Packaging Products
433. Wockhardt
434. Wyeth
435. XBiotech
436. Xbrane Biopharma
437. XOMA
438. YangZhong Wealth Metal
439. Youlyy Industrial
440. Ypsomed Delivery Systems
441. Zealand Pharma
442. Zeon Chemicals
443. Zensun
444. Zhejiang Hisun Pharmaceutical
445. Zhejiang Huahai Pharmaceutical
446. Zhejiang Xinkang Pharmaceutical Glass
447. Zogenix
448. Zydus Cadila
449. ZymoGenetics


1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. Executive Summary
3. Introduction to Prefilled Syringes
3.1. Chapter Overview
3.2. History of Prefilled Syringes
3.3. Benefits of Prefilled Syringes over Traditional Injectable Devices
3.3.1. Benefits for Healthcare Professionals and End Users
3.3.2. Benefits for Manufacturers
3.3.3. Shift of Existing Formulations to Prefilled Syringes
3.4. Prefilled Syringes Components
3.5. Classification of Prefilled Syringes
3.5.1. Classification by Manufacturing Material of the Barrel
3.5.1.1. Glass: Historical Material of Choice
3.5.1.2. Limitations of Glass Prefilled Syringes
3.5.1.3. Addressing the Limitations of Glass Prefilled Syringes
3.5.1.4. Advantages of Plastic Prefilled Syringes
3.5.1.5. Slow Adoption of Plastic Prefilled Syringes
3.5.1.6. Factors Likely to Drive the Use of Plastic Prefilled Syringes
3.5.2. Classification by Number of Chambers in the Barrel
3.5.3. Classification by Type of Needle
3.5.4. Classification by Type of Processing
3.6. Critical Attributes of a Prefilled Syringe Design
3.7. Prefilled Syringe Systems Available in the Market
3.7.1. Glass Prefilled Syringes
3.7.2. Plastic Prefilled Syringes
3.8. Technological Developments in Prefilled Syringes
4. Needlestick Injuries
4.1. Chapter Overview
4.2. Incidence and Cost Burden
4.3. Government Legislations for Needlestick Injury Prevention
4.4. Safety Mechanisms used by Prefilled Syringe Manufacturers
4.4.1. Safety Systems: Add-On Devices
4.4.1.1. Becton Dickinson
4.4.1.2. Gerresheimer
4.4.1.3. West Pharmaceutical Services
4.4.1.4. Vetter Pharma
4.4.1.5. Tip-Top
4.4.1.6. Credence MedSystems
4.4.1.7. Schreiner MediPharm
4.4.2. Safety Systems: Integrated Devices
4.4.2.1. Unilife Corporation: Unifill Safety Syringes
4.4.2.2. MedPro Safety Products: Prefilled Safety Syringes
4.4.2.3. Taisei Kako: Fulject™ Safety Syringes
4.4.2.4. Globe Medical Tech: Vacuum Retract Safety Syringes
4.4.2.5. US Medical Instruments: SafeSnap®
4.4.2.6. Revolutions Medical: RevVac™ Safety Syringes
4.4.2.7. MedicalChain International: MySafill® iPPFSS
4.4.2.8. Owen Mumford: Unisafe™
5. Regulatory Landscape for Prefilled Syringes
5.1. Chapter Overview
5.2. Regulatory Approval of Combination Products in the US
5.2.1. Overview
5.2.2. Historical Background
5.2.3. Regulatory Bodies and their Role in Product Approval
5.2.4. Regulatory Approval Pathway for Prefilled Syringes
5.3. Regulatory Approval of Combination Products in Europe
5.3.1. Overview
5.3.2. Regulatory Bodies and their Role in Product Approval
5.3.3. Regulatory Approval for Prefilled Syringes
5.4. Regulatory Approval of Combination Products in Canada
5.4.1. Overview
5.4.2. Regulatory Bodies and their Role in Product Approval
5.4.3. Regulatory Approval of Prefilled Syringes
5.5. Regulatory Approval of Combination Products in Brazil
5.5.1. Overview
5.5.2. Regulatory Bodies and their Role in Product Approval
5.5.3. Regulatory Approval of Prefilled Syringes
5.6. Regulatory Approval of Combination Products in Mexico
5.6.1. Overview
5.6.2. Regulatory Bodies and their Role in Product Approval
5.6.3. Regulatory Approval of Prefilled Syringes
5.7. Regulatory Approval of Combination Products in Argentina
5.7.1. Overview
5.7.2. Regulatory Bodies and their Role in Product Approval
5.7.3. Regulatory Approval of Prefilled Syringes
5.8. Regulatory Approval of Combination Products in Australia
5.8.1. Overview
5.8.2. Regulatory Bodies and their Role in Product Approval
5.8.3. Regulatory Approval of Prefilled Syringes
5.9. Regulatory Approval of Combination Products in Japan
5.9.1. Overview
5.9.2. Regulatory Bodies and their Role in Product Approval
5.9.3. Regulatory Approval of Prefilled syringes
5.10. Regulatory Approval of Combination Products in China
5.10.1. Overview
5.10.2. Regulatory Bodies and their Role in Product Approval
5.10.3. Regulatory Approval of Prefilled syringes
5.11. Regulatory Approval of Combination Products in India
5.11.1. Overview
5.11.2. Regulatory Bodies and their Role in Product Approval
5.11.3. Regulatory Approval of Prefilled Syringes
5.12. Regulatory Approval of Combination Products in South Korea
5.12.1. Overview
5.12.2. Regulatory Bodies and their Role in Product Approval
5.12.3. Regulatory Approval of Prefilled Syringes
5.13. Regulatory Approval of Combination Products in Saudi Arabia
5.13.1. Overview
5.13.2. Regulatory Bodies and their Role in Product Approval
5.14. Regulatory Approval of Prefilled Syringes
5.15. Regulatory Approval of Combination Products in United Arab Emirates
5.15.1. Overview
5.15.2. Regulatory Bodies and their Role in Product Approval
5.15.3. Regulatory Approval of Prefilled Syringes
6. Growth Drivers
6.1. Chapter Overview
6.2. Increase in the Number of Self-Injecting Patients
6.3. Increase in Incidences of Chronic Diseases
6.4. Changing Patient Demographics
6.5. Growth of Biologics and Biosimilars
6.6. Changing Pharmaceutical Strategies
6.7. Increasing Focus on the Prevention of Needlestick Injuries
6.8. Convergence of Prefilled Syringes with Autoinjectors/Pen-Injectors
7. Products Available in Prefilled Syringes
7.1. Chapter Overview
7.2. Drugs Approved in Prefilled Syringes, 2013-2016
7.3. Drugs Approved in Prefilled Syringes: Therapeutic Area Analysis
7.4. Leading Drugs in Prefilled Syringes, 2016
7.5. Other Drugs Available in Prefilled Syringes, 2016
7.6. Case Studies
7.6.1. HUMIRA® (Adalimumab), AbbVie / Eisai
7.6.1.1. Indications and Dosage Forms
7.6.1.2. Shift from Vials to Syringes
7.6.2. Enbrel® (Etanercept), Amgen / Pfizer / Takeda
7.6.2.1. Indications and Dosage Forms
7.6.2.2. Shift from Vials to Syringes
7.6.3. Copaxone® (Glatiramer Acetate), Teva Pharmaceuticals
7.6.3.1. Indications and Dosage Forms
7.6.3.2. Shift from Vials to Syringes
7.6.4. Lovenox® / Clexane® (Enoxaparin sodium), Sanofi / GL Pharma / Italfarmaco
7.6.4.1. Indications and Dosage Forms
7.6.4.2. Shift from Vials to Prefilled Syringes
7.6.5. Abilify Maintena® (Aripiprazole Controlled Release), Otsuka Pharmaceutical / Lundbeck
7.6.5.1. Indications and Dosage Forms
7.6.5.2. Shift from Vials to Syringes
7.7. Pipeline Drugs in Prefilled Syringes
7.8. Pipeline Drugs: Therapeutic Area Analysis
7.9. Drugs Available by Therapeutic Classes
7.9.1. Anti-Rheumatics
7.9.1.1. Approved Injectables
7.9.1.2. Biosimilars
7.9.2. Multiple Sclerosis Drugs
7.9.2.1. Approved Injectables
7.9.2.2. Biosimilars
7.9.3. Antivirals
7.9.3.1. Approved Injectables
7.9.3.2. Biosimilars
7.9.4. Anticoagulants
7.9.4.1. Approved Injectables
7.9.4.2. Biosimilars / Generics
7.9.5. Vaccines
7.9.6. Diabetes Drugs
7.9.6.1. Insulin Market
7.9.6.2. Approved Injectables
7.9.6.3. Biosimilars
8. Likely Candidates for Prefilled Syringes
8.1. Chapter Overview
8.2. Marketed Molecules
8.2.1. Marketed Molecules: Likely Candidates for Prefilled Syringes
8.3. Pipeline Molecules
8.3.1. Pipeline Molecules: Most Likely Candidates for Prefilled Syringes
8.3.2. Pipeline Molecules: Likely Candidates for Prefilled Syringes
8.3.3. Pipeline Molecules: Less Likely Candidates for Prefilled Syringes
8.4. Vaccines: Likely Candidates for Prefilled Syringes
9. Manufacturers of Prefilled Syringes
9.1. Chapter Overview
9.2. Key Prefilled Syringe Manufacturers Based in North America
9.2.1. Becton Dickinson
9.2.1.1. Company Overview
9.2.1.2. Financial Performance
9.2.1.3. Glass Prefilled Systems
9.2.1.3.1. BD Hypak™ Prefilled Syringe
9.2.1.3.2. Luer Products
9.2.1.3.3. Staked Needle Products
9.2.1.3.4. BD Neopak™ Prefilled Syringe
9.2.1.4. Plastic Prefilled Systems
9.2.1.4.1. BD Sterifill™ Syringe Systems
9.2.1.5. Other Prefilled Delivery Systems
9.2.1.5.1. BD Uniject™
9.2.1.5.2. BD Soluvia™
9.2.1.6. BD Prefilled Technology Solutions
9.2.1.7. Recent Developments
9.2.1.7.1. Deals and Agreements
9.2.1.7.2. Expansions
9.2.1.8. Future Outlook
9.2.2. Unilife Corporation
9.2.2.1. Company Overview
9.2.2.2. Financial Performance
9.2.2.3. Glass Prefilled Syringe
9.2.2.3.1. Unifill® Syringes
9.2.2.3.2. EZMix™ Syringes
9.2.2.4. Wearable Injector Platform
9.2.2.5. Ocular Delivery Systems
9.2.2.6. Novel Delivery Systems
9.2.2.8. Recent Developments
9.2.2.8.1. Deals and Agreements
9.2.2.8.1.1. Partnership with Amgen
9.2.2.8.1.2. Partnership with MedImmune
9.2.2.8.1.3. Partnership with AbbVie
9.2.2.8.1.4. Partnership with Global Pharma Company
9.2.2.8.1.5. Partnership with Novartis
9.2.2.8.1.6. Partnership with Hikma
9.2.2.8.1.7. Partnership with Sanofi
9.2.2.8.1.8. Partnership with Biodel
9.2.2.8.2. Expansion
9.2.2.8.3. Fundings
9.2.2.9. Future Outlook
9.2.3. West Pharmaceutical Services
9.2.3.1. Company Overview
9.2.3.2. Financial Performance
9.2.3.3. Plastic Prefilled Systems
9.2.3.3.1. Daikyo Crystal Zenith® RU Prefilled Syringe
9.2.3.4. Drug Reconstitution Systems
9.2.3.5. Prefilled Technology Solutions
9.2.3.6. Recent Developments
9.2.3.6.1. Growth of CZ Syringes
9.2.3.6.2. Launch of NovaPure Plunger for Higher Volume Injections
9.2.3.6.3. Growth in Pharma Emerging Markets (Brazil, China and India)
9.2.3.6.4. Manufacturing Expansion
9.2.3.6.5. Development Pipeline
9.2.3.7. Future Outlook
9.3. Key Prefilled Syringe Manufacturers Based in Europe
9.3.1. Aguettant
9.3.1.1. Company Overview
9.3.1.2. Aguettant Prefilled Syringes
9.3.1.3. Aguettant Self-Injector Pen
9.3.1.4. Recent Developments
9.3.1.5. Future Outlook
9.3.2. Gerresheimer
9.3.2.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Glass Prefilled Systems
9.3.2.3.1. Gx® Glass Syringes
9.3.2.4. Plastic Prefilled Systems
9.3.2.4.1. ClearJect® Prefilled Syringes
9.3.2.4.2. Gx RTF® Clearject® Needle Syringe
9.3.2.5. Self-Injection Devices
9.3.2.6. Prefilled Technology Solutions
9.3.2.7. Recent Developments
9.3.2.7.1. Expansion of Product Portfolio
9.3.2.7.2. Expansion of Manufacturing Capacity for RTF syringes
9.3.2.7.3. Expansion of Capacity of Medical Plastic Systems
9.3.2.7.4. Growth in Emerging Economies
9.3.2.8. Future Outlook
9.3.3. Nuova Ompi
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Glass Prefilled Systems
9.3.3.3.1. EZ-Fill® Syringes
9.3.3.4. Recent Developments
9.3.3.4.1. New Corporate Branding
9.3.3.4.2. Capacity Expansion across the Glass Divisions
9.3.3.4.3. Twist-Off Closure System for Prefilled Syringes
9.3.4. SCHOTT
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Glass Prefilled Syringes
9.3.4.3.1. syriQ® (Previously Forma 3s) Glass Syringes
9.3.4.3.2. syriQ™ InJentle Syringes
9.3.4.4. Plastic Prefilled Syringes
9.3.4.4.1. TopPac® Polymer Syringes
9.3.4.5. Recent Developments
9.3.4.5.1. TopPac® Syringe System for Sensitive Drugs
9.3.4.5.2. TopPac® Syringe System for Highly Viscous Drugs
9.3.4.5.3. TopPac® 20 ml Syringe System for Infusion Therapy
9.3.4.5.4. Rebranding the Glass Prefilled Syringes
9.3.4.5.5. New Closure Systems for Plastic / Glass Prefilled System
9.3.4.5.6. Growth in the Pharma Emerging Markets (Brazil, China, India, Indonesia and Russia)
9.3.4.5.7. Expansion of Production Facilities in the US and EU
9.3.4.6. Future Outlook
9.3.5. Vetter Pharma
9.3.5.1. Company Overview
9.3.5.2. Lyo-Ject® Glass Prefilled Syringe
9.3.5.3. Vetter-Ject®
9.3.5.4. Recent Developments
9.3.5.4.1. Capacity Expansion
9.3.5.4.2. Collaboration with West Pharmaceutical Services
9.3.5.5. Future Outlook
9.4. Key Prefilled Syringes Manufacturers Based in Asia Pacific
9.4.1. Nipro Corporation (Acquired MGlas)
9.4.1.1. Company Overview
9.4.1.2. Financial Performance
9.4.1.3. Glass Prefilled Systems
9.4.1.4. Plastic Prefilled Systems
9.4.1.5. Recent Developments
9.4.1.6. Future Outlook
9.4.2. Weigao Group Pharmaceutical Packaging Products Company
9.4.2.1. Company Overview
9.4.2.2. Financial Performance
9.4.2.3. WeGo Glass Prefilled Syringe
9.4.2.4. Future Outlook
9.4.3. Terumo Corporation
9.4.3.1. Company Overview
9.4.3.2. Financial Performance
9.4.3.3. PLAJEX™: Plastic Prefilled Syringe
9.4.3.4. Safety Devices: Add-On Devices
9.4.3.5. Future Outlook
9.5. Other Manufacturers
9.5.1. Arte Corporation
9.5.2. J.O. Pharma (Subsidiary of Otsuka Holdings)
9.5.3. Roselabs Group
9.5.4. Shandong Zibo Minkang Pharmaceutical packing
9.5.5. Shandong Pharmaceutical Glass
9.5.6. Taisei Kako
9.5.7. Yangzhong Wealth Metal
9.5.8. Youlyy Industrial
9.6. Mapping the Competitive Landscape
10. Prefilled Syringe Component Manufacturers
10.1. Chapter Overview
10.2. West Pharmaceutical Services
10.2.1. Overview
10.2.2. Financial Performance
10.2.3. Prefilled Syringe Components
10.2.3.1. Plungers
10.2.3.2. Needle Shields and Tip Caps
10.2.3.3. Backstops
10.2.4. Manufacturing Facilities
10.3. Datwyler
10.3.1. Overview
10.3.2. Financial Performance
10.3.3. Prefilled Syringe Components
10.3.3.1. Plungers
10.3.3.2. Needle Shields and Tip Caps
10.3.4. Manufacturing of Prefilled Syringe Components
10.4. Aptar Stelmi
10.4.1. Overview
10.4.2. Financial Performance
10.4.3. Prefilled Syringe Components
10.4.3.1. Plungers
10.4.3.2. Needle Shields
10.4.3.3. Tip Caps
10.4.3.4. Stoppers
11. Fill-Finish Service Providers for Prefilled Syringes
11.1. Chapter Overview
11.2. Fill-Finish Processing of Prefilled Syringes
11.2.1. Steps Involved in Fill-Finish Process
11.2.2. Methods of Filling and Stoppering of Prefilled Syringes
11.2.3. Prefilled Syringe Filling Technologies
11.3. Outsourcing of Fill-Finish Operations
11.4. Growth Considerations
11.5. Fill-Finish Service Providers
11.5.1. Key Fill-Finish Service Provider(s): North America
11.5.1.1. BioPharma Solutions
11.5.1.2. Catalent
11.5.1.3. Pfizer CentreOne
11.5.2. Key Fill-Finish Service Provider(s): Latin America
11.5.2.1. PiSA Farmaceutica
11.5.3. Key Fill-Finish Service Provider(s): Europe
11.5.3.1. Boehringer Ingelheim BioXcellence
11.5.3.2. ROVI CM
11.5.4. Key Fill-Finish Service Provider(s): Asia Pacific
11.5.4.1. Cipla BioTec
11.5.4.2. DM Bio
11.5.4.3. Genovior Biotech
11.5.5. Key Fill-Finish Service Provider(s): Middle East
11.5.5.1. The Birgi Mefar Group
12. Specialty Prefilled Syringes
12.1. Chapter Overview
12.2. Prefilled Flush Syringes
12.2.1. Overview
12.2.2. Prefilled Flush Syringes Available in the Market
12.2.3. Advantages of Prefilled Flush Syringes
12.3. Prefilled Diluent Syringes
12.3.1. Overview
12.3.2. Lyophilized Drugs Available in Prefilled Diluent System
12.3.3. Advantages of Prefilled Diluent Syringe Systems
12.4. Contrast Agent Prefilled Syringes
12.4.1. Overview
12.4.2. Contrast Agents Available in Prefilled Syringes
12.4.3. Advantages of Using Prefilled Syringe for Contrast Agents
13. Global Prefilled Syringes Market Forecast, 2016-2026
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. Global Market Size and Forecast
13.3.1. Prefilled Syringes for Vaccines
13.3.2. Prefilled Syringes for Drugs
13.3.2.1. Prefilled Syringes for Anticoagulants
13.3.2.2. Prefilled Syringes for Diabetes Drugs
13.3.2.3. Prefilled Syringes for Multiple Sclerosis Drugs
13.3.2.4. Prefilled Syringes for Anti-Arthritic Drugs
13.3.2.5. Prefilled Syringes for Anti-Anemic Drugs
13.3.2.6. Prefilled Syringes for Other Drug Classes
13.3.3. Specialty Prefilled Syringes
13.3.4. Overall Global Market Size
13.4. Prefilled Syringe Market Forecast by Regions
13.4.1. North America Prefilled Syringes Market
13.4.2. EU Prefilled Syringes Market
13.4.3. Asia Pacific Prefilled Syringes Market
13.4.4. Latin America Prefilled Syringes Market
13.4.5. Middle East and Africa Prefilled Syringes Market
13.4.6. Prefilled Syringes Market Attractiveness Analysis by Region
13.5. Prefilled Syringes Market Forecast by Type of Material
13.6. Prefilled Syringes Market Forecast by Nature of Molecule
13.6.1. Prefilled Syringes Market Attractiveness Analysis by Nature of Molecule
14. Case Study: Autoinjectors
14.1. Chapter Overview
14.2. Autoinjectors: Market Overview
14.3. Key Players
14.3.1. Bespak
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.2.1. Autoinjectors
14.3.1.2.1.1. Syrina™
14.3.1.2.1.2. ASI Autoinjector™
14.3.1.2.1.3. OTS Autoinjector™
14.3.2. DALI Medical Devices
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.2.1. Autoinjectors
14.3.2.2.1.1. SAN-L
14.3.2.2.1.2. SAN-P
14.3.2.2.1.3. SAN-DV
14.3.2.2.1.4. SAN-DV Pro
14.3.3. Elcam Medical (E3D Elcam Drug Delivery Devices)
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.2.1. Autoinjectors
14.3.3.2.2. Flexi-Q Disposable Autoinjector
14.3.3.2.2.1. Flexi-Q PFS
14.3.3.2.2.2. Flexi-Q HV
14.3.3.2.2.3. Flexi -Q DV
14.3.3.2.3. Flexi-Q Reusable Autoinjectors
14.3.3.2.3.1. Flexi-Q mMU
14.3.3.2.3.2. Flexi-Q eMU
14.3.4. Nuance Designs
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.2.1. Fusion™ Autoinjector
14.3.4.2.2. Quantum™ Autoinjector
14.3.5. Owen Mumford
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.2.1. Autoinjectors
14.3.5.2.1.1. Autoject® Micro
14.3.5.2.1.2. Autoject® 2
14.3.5.2.1.3. Autoject® Mini
14.3.5.2.1.4. Autoject® Uni
14.3.5.2.1.5. Autoject® Multi
14.3.5.2.1.6. Autoject® Flex
14.3.6. Scandinavian Health Limited (SHL) Group
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.2.1. Two-Step Disposable Autoinjectors
14.3.6.2.1.1. Amber (Pushclick Technology)
14.3.6.2.1.2. Molly®
14.3.6.2.1.3. Molly® RNS
14.3.6.2.1.4. Molly® 2.25
14.3.6.2.1.5. Molly® C
14.3.6.2.1.6. NAISA® (Negasai™ Spring Technology)
14.3.6.2.2. Three-Step Disposable Autoinjectors
14.3.6.2.2.1. DAI®
14.3.6.2.2.2. DAI®-RNS
14.3.6.2.2.3. DAI®-R
14.3.6.2.2.4. SDI-MIX®+NIT™ (Needle Isolation Technology and Twist and Mix Mechanism)
14.3.6.2.2.5. VSDI-MIX™
14.3.6.2.2.6. PSDI®
14.3.6.2.3. PPI® Injector (Rotaject Pressure Release Technology)
14.3.7. Union Medico
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.2.1. 45˚ Autoinjector
14.3.7.2.1.1. 45˚/S Autoinjector
14.3.7.2.1.2. 45˚/M Autoinjector
14.3.7.2.1.3. 45˚/R Autoinjector
14.3.7.2.2. 90˚ Autoinjector
14.3.7.2.2.1. 90˚/S Autoinjector
14.3.7.2.2.2. 90˚/ M Autoinjector
14.3.7.2.2.3. 90˚/ XL Autoinjector
14.3.7.2.2.4. SuperGrip™ Autoinjector
14.3.7.2.2.5. Exclusive™ Autoinjector
14.3.8. Ypsomed Delivery Systems
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.2.1. Pen Injectors
14.3.8.2.2. Autoinjectors
14.3.8.2.2.1. YpsoMate® and YpsoMate® 2.25
14.3.8.2.2.2. VarioJect™
14.3.8.2.2.3. YpsoMate® Smart
15. Recent Developments and Applications of Prefilled Syringes
15.1. Chapter Overview
15.2. Prefilled Syringes for Lyophilized Drugs
15.2.1. Prefilled Diluent Syringes
15.2.2. Prefilled Dual / Multi-Chamber Syringes
15.2.2.1. Lyophilized Drugs Available in Dual / Multi-Chamber Prefilled Syringe
15.2.2.2. Prefilled Dual-Chambered Pen Injectors for Lyophilized Drugs
15.3. Multilayer Plastic Prefilled Syringes with Oxygen Barrier
15.4. Novel Lubrication Technology for Prefilled Syringes
15.5. Advancement in Terminal Sterilization of Prefilled Syringes
15.5.1. Noxilizer’s Nitrogen Dioxide Sterilization Technology
16. SWOT Analysis
16.1. Chapter Overview
16.2. Strengths
16.3. Weaknesses
16.4. Opportunities
16.5. Threats
17. Conclusion
17.1. Prefilled Syringes have Emerged as the Preferred Administration Device for Parenteral Drugs
17.2. Plastic Syringes are Anticipated to Grow at Faster Rate than Glass Syringes
17.3. Emergence of Biologics, Technological Advances and Many Other Factors will Sustain the Growth
17.4. Although the Market is Consolidated, New Entrants with Innovative Technologies are expected to Drive Future Evolution
17.5. CMOs are an Integral Part of the Value Chain, Providing Aseptic Fill / Finish Services
17.6. The Prefilled Syringes Market is Poised to Grow at a Moderate Pace over the Coming Decade
17.7. Concluding Remarks
18. Interview Transcripts
18.1. Chapter Overview
18.2. Kirti Maheshwari, Chief Technical Officer, Intas Pharmaceuticals, Q3 2016
18.3. Kevin Cancelliere and Tibor Hlobik, Marketing Directors, West Pharmaceutical Services, Q2 2015
18.4. Rondald Wheet, Chief Executive Officer, Revolutions Medical, Q2 2015
18.5. Matthew Young, Founder and Chief Technology Officer, Oval Medical Technologies, Q2 2014
19. Appendix 1: Tabulated Data
20. Appendix 2: List of Companies
LIST OF FIGURES
Figure 2.1 Prefilled Syringes Market Evolution: 2016, 2021, and 2026 (Number of Units, Million)
Figure 2.2 Prefilled Syringes Market Landscape, 2016-2026: Geographic Trends
Figure 2.3 Prefilled Syringes Market Attractiveness Analysis by Region
Figure 2.4 Prefilled Syringes Market Attractiveness Analysis by Nature of Molecule
Figure 3.1 Glass Prefilled Syringes: Advantages and Disadvantages
Figure 3.2 Properties of Cyclic Olefin Copolymer and Cyclo Olefin Polymer
Figure 3.3 Plastic Prefilled Syringes: Advantages and Disadvantages
Figure 3.4 Critical Design Parameters of Prefilled Syringes
Figure 3.5 Prefilled Syringes: Market Landscape by Manufacturers
Figure 3.6 Technological Evolution of Prefilled Syringes
Figure 4.1 Worldwide Evolution in Healthcare Safety Legislation
Figure 5.1 Global Regulations Related to Prefilled Syringes
Figure 5.2 Approval Pathway for Combination Products in the US
Figure 5.3 Approval Pathway for Combination Products in Canada
Figure 5.4 Approval Pathway for Combination Products in China
Figure 6.1 Global Prevalence of Diabetes: Distribution by Countries, 2015 (Million, %)
Figure 6.2 Numbers of Biologics Approved by the USFDA, 2009-2016
Figure 6.3 Top Selling Biologics: Estimated Patent Expiry
Figure 7.1 Approved Drugs: Therapeutic Area Analysis (2013-2016)
Figure 7.2 Sales of Leading Drugs Available in Prefilled Syringes, 2016 (USD Million)
Figure 7.3 HUMIRA®: Approval Timeline (US, EU and Japan)
Figure 7.4 HUMIRA®: Approval Timeline for Various Dosage Forms (US and EU)
Figure 7.5 HUMIRA®: Annual Sales, 2003-Q3 2016 (USD Million)
Figure 7.6 Enbrel®: Approval Timeline (US and EU)
Figure 7.7 Enbrel®: Approval Timeline for Various Dosage Forms (US and EU)
Figure 7.8 Enbrel®: Annual Sales in the US and Canada, 2002-2015 (USD Million)
Figure 7.9 Enbrel®: Annual Sales outside US and Canada, 2010-2015 (USD Million)
Figure 7.10 Copaxone ®: Annual Sales, 2001-Q3 2016 (USD Million)
Figure 7.11 Copaxone ®: Distribution by Vials and Prefilled Syringes, 2000-2008 (Million Units)
Figure 7.12 Lovenox®: Approval Timeline (US)
Figure 7.13 Lovenox®: Global Annual Sales, 2009- Q3 2016 (EUR Million)
Figure 7.14 Abilify Maintena®: Approval Timeline (US, Canada, Europe, Japan)
Figure 7.15 Pipeline Drugs: Therapeutic Area Analysis
Figure 7.16 Number of Approved / Pipeline Biosimilars of Anti-Rheumatics
Figure 7.17 Number of Approved / Pipeline Biosimilars of Multiple Sclerosis Drugs
Figure 7.18 Number of Approved / Pipeline Biosimilars of Antivirals
Figure 7.19 Number of Approved / Pipeline Biosimilars and Generics of Anticoagulants
Figure 7.20 Number of Approved / Pipeline Biosimilars of Diabetes Drugs
Figure 8.1 Marketed Molecules: Parameters and Scoring Criteria
Figure 8.2 Pipeline Molecules: Parameters and Scoring Criteria
Figure 9.1 BD Medical: Annual Revenues, 2011-2016 (USD Billion)
Figure 9.2 BD Medical: Revenue Distribution by Sub-Segments, 2016 (USD Billion)
Figure 9.3 Unilife Corporation: Annual Revenues, FY 2011/12-2015/16 (USD Million)
Figure 9.4 West Pharmaceutical Services: Annual Revenues, 2011-Q3 2016 (USD Million)
Figure 9.5 West Pharmaceutical Services: Revenue Distribution by Business Segments, 2015 (USD Million)
Figure 9.6 West Pharmaceutical Services: Annual Revenues of Delivery Systems Segment, 2011-2015 (USD Million)
Figure 9.7 West Pharmaceutical Services: Annual Revenues in the US and Overseas, 2011-2015 (USD Million)
Figure 9.8 West Pharmaceutical Services: Revenue Distribution by Region, 2015 (USD Million)
Figure 9.9 Gerresheimer: Annual Revenues, 2011-Q3 2016 (EUR Million)
Figure 9.10 Gerresheimer: Revenue Distribution by Business Divisions, 2015 (EUR Million)
Figure 9.11 Gerresheimer: Revenue Distribution by Region, 2011- 2015 (EUR Million)
Figure 9.12 SCHOTT: Annual Revenues, FY 2012/13-FY 2014/15 (EUR Million)
Figure 9.13 SCHOTT: Revenue Distribution by Business Divisions, FY 2014/15 (EUR Million)
Figure 9.14 SCHOTT: Revenue Distribution by Region, FY 2014/15 (EUR Million)
Figure 9.15 Nipro Corporation: Annual Revenues, 2011/12-2015/16 (YEN Billion)
Figure 9.16 Nipro Corporation: Revenue Distribution by Business Divisions, 2015/16 (YEN Billion)
Figure 9.17 Nipro Corporation: Revenue Distribution by Region, 2015/16 (YEN Billion)
Figure 9.18 Nipro Corporation: Revenue Distribution by Region, 2011/12-2015/16 (YEN Billion)
Figure 9.19 Weigao: Annual Revenues of Prefilled Syringes, 2011-H1 2016 (RMB Million)
Figure 9.20 Weigao: Revenue Distribution by Product Category, 2015 (RMB Million)
Figure 9.21 Terumo Corporation: Annual Revenues, FY 2011-H1 2016 (YEN Billion)
Figure 9.22 Terumo Corporation: Revenue Distribution by Business Divisions, FY 2015/16 (YEN Billion)
Figure 9.23 Terumo Corporation: Revenue Distribution by Region, FY 2015/16 (YEN Billion)
Figure 9.24 Glass Prefilled Syringes: Product Landscape Analysis
Figure 9.25 Polymer Prefilled Syringes: Product Landscape Analysis
Figure 10.1 Datwyler Group: Annual Revenues, 2011-H1 2016 (CHF Million)
Figure 10.2 Datwyler Group: Revenue Distribution by Business Divisions, 2015 (CHF Million)
Figure 10.3 Aptar Stelmi: Annual Revenues, 2013-2015 (USD Million)
Figure 11.1 Prefilled Syringes: Fill-Finish Process
Figure 13.1 Prefilled Syringes Price Curve, 2016-2026 (USD per unit)
Figure 13.2 Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (Million Units)
Figure 13.3 Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (USD Million)
Figure 13.4 Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (Million Units)
Figure 13.5 Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (USD Million)
Figure 13.6 Prefilled Syringes Market for Anticoagulants, 2016: Distribution by Nature of Molecule (%)
Figure 13.7 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (Million Units)
Figure 13.8 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (USD Million)
Figure 13.9 Prefilled Syringes Market for Diabetes Drugs, 2016: Distribution by Nature of Molecule (%)
Figure 13.10 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (Million Units)
Figure 13.11 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (USD Million)
Figure 13.12 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
Figure 13.13 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (Million Units)
Figure 13.14 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (USD Million)
Figure 13.15 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
Figure 13.16 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (Million units)
Figure 13.17 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (USD Million)
Figure 13.18 Prefilled Syringes Market for Anti-Anemic Drugs, 2016: Distribution by Nature of Molecule (%)
Figure 13.19 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (Million Units)
Figure 13.20 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (USD Million)
Figure 13.21 Prefilled Syringes Market for Other Drug Classes, 2016 and 2026: Distribution by Nature of Molecule (%)
Figure 13.22 Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (Millions Units)
Figure 13.23 Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Figure 13.24 Global Prefilled Syringes Market, 2016-2026: Base Scenario (Million Units)
Figure 13.25 Global Prefilled Syringes, Units Growth by Category, 2016-2026 (Base Scenario, Million Units)
Figure 13.26 Global Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Figure 13.27 Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Base Scenario, USD Million)
Figure 13.28 Prefilled Syringes Market: Distribution by Regions, 2016 and 2026 (%)
Figure 13.29 North America Prefilled Syringes Market, 2016-2026: Base Scenario (Million Units)
Figure 13.30 North America Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Figure 13.31 EU Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Figure 13.32 EU Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
Figure 13.33 Asia Pacific Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Figure 13.34 Asia Pacific Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
Figure 13.35 Latin America Prefilled Syringes Market, 2016 - 2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Figure 13.36 Latin America Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
Figure 13.37 Middle East and Africa Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Figure 13.38 Middle East and Africa Prefilled Syringes Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (USD Million)
Figure 13.39 Prefilled Syringes Market Attractiveness Analysis by Region
Figure 13.40 Prefilled Syringes Market, 2016-2026: Distribution by Type of Material, Base Scenario (Million Units)
Figure 13.41 Prefilled Syringes Market, 2016-2026: Distribution by Type of Material, Base Scenario (USD Million)
Figure 13.42 Prefilled Syringes Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (Million Units)
Figure 13.43 Prefilled Syringes Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (USD Million)
Figure 13.44 Prefilled Syringes Market Attractiveness Analysis by Nature of Molecule
Figure 14.1 Bespak Injectables: Autoinjectors
Figure 14.2 Bespak Injectables: Syrina™ Autoinjectors
Figure 14.3 DALI Medical Devices: Autoinjectors
Figure 14.4 Elcam Medical: Products
Figure 14.5 Elcam Medical: Flexi-Q Autoinjectors
Figure 14.6 Owen Mumford: Cartridge-Based Injection Pens
Figure 14.7 Owen Mumford: Autoinjectors
Figure 14.8 SHL Medical: Product Portfolio
Figure 14.9 SHL Medical: Prefilled Syringe Based Autoinjectors
Figure 14.10 SHL Medical: Cartridge Based Autoinjectors
Figure 14.11 SHL Medical: Two-Step Autoinjectors
Figure 14.12 SHL Medical: Three-Step Autoinjectors
Figure 14.13 Union Medico: 45˚ Autoinjector Portfolio
Figure 14.14 Union Medico: Types of 45˚/R Autoinjector
Figure 14.15 Union Medico: Types of 90˚ Autoinjectors
Figure 14.16 Ypsomed: Cartridge Based Pen injectors
Figure 14.17 Ypsomed: Cartridge Based Dual-Chamber Pen injectors
Figure 14.18 Ypsomed: Prefilled Syringe or Cartridge Based Autoinjectors
Figure 16.1 SWOT Analysis
Figure 16.2 Common Medication Errors
Figure 16.3 Common Sources of Medication Errors
Figure 16.4 Prefilled Syringe Recalls: Distribution by Type of Issue, 2003-2016
Figure 17.1 Fill and Finish Service Providers: Distribution by Region
Figure 17.2 Prefilled Syringes Market: 2016, 2021 and 2026 (Billion Units)
Figure 17.3 Prefilled Syringes Market: 2016, 2021, and 2026 (USD Billion)
LIST OF TABLES
Table 3.1 Drugs: Shifted from Vials to Prefilled Syringe Systems
Table 3.2 Components of Prefilled Syringes
Table 3.3 Classification of Prefilled Syringes
Table 3.4 Advantages of Glass as Barrel Material
Table 3.5 Prefilled Glass Syringe Recalls
Table 3.6 Advantages of Plastic Polymers as Barrel Material
Table 3.7 Pharmaceutical Filling Lines: Process Flow by Type of Prefilled Syringe
Table 3.8 Prefilled Syringe Systems Available in the Market, 2016: A Comparison by Manufacturer
Table 3.9 Glass Prefilled Syringes Available in the Market, 2016
Table 3.10 Plastic Prefilled Syringes Available in the Market, 2016
Table 4.1 Add-On Safety Device Manufacturers
Table 4.2 Integrated Prefilled Safety Device Manufacturers
Table 5.1 USFDA Centers for Drugs and Device Approval
Table 5.2 US: Regulatory Review Timelines
Table 5.3 Regulatory Bodies in EU5 Countries
Table 5.4 Saudi Arabia: Regulatory Review Timelines
Table 6.1 Population above 60 years (Million), 2015, 2030 and 2050
Table 6.2 Autoinjector / Pen-injector Systems Approved in 2013-2016
Table 6.3 Autoinjectors / Pen-injectors (Using Prefilled Syringes) Available in the Market
Table 7.1 Drugs Approved in Prefilled Syringes, 2013-2016
Table 7.2 Other Drugs Sold in Prefilled Syringes
Table 7.3 Pipeline Drugs Using Prefilled Syringe System
Table 7.4 Leading Anti-Rheumatic Drugs
Table 7.5 Anti-Rheumatics Drugs Available in Prefilled Syringes
Table 7.6 Anti-Rheumatic Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 7.7 Leading Multiple Sclerosis Drugs
Table 7.8 Multiple Sclerosis Drugs Available in Prefilled Syringes
Table 7.9 Multiple Sclerosis Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 7.10 Leading Antiviral Drugs
Table 7.11 Antiviral Drugs Available in Prefilled Syringes
Table 7.12 Antiviral Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 7.13 Leading Anticoagulants
Table 7.14 Anticoagulants Available in Prefilled Syringes
Table 7.15 Anticoagulants Available in Prefilled Format: Patent Expiry and Biosimilars /Generics Development
Table 7.16 Leading Vaccines
Table 7.17 Vaccines Available in Prefilled Syringes
Table 7.18 Leading Diabetes Drugs
Table 7.19 Diabetes Drugs Available in Prefilled Insulin Pen
Table 7.20 Diabetes Drugs Available in Prefilled Format: Patent Expiry and Biosimilar Development
Table 8.1 Marketed Molecules: Most Likely / Likely / Less likely Candidates for Prefilled Syringes
Table 8.2 Pipeline Molecules: Most Likely Candidates for Prefilled Syringes
Table 8.3 Pipeline Molecules: Likely Candidates for Prefilled Syringes
Table 8.4 Pipeline Molecules: Less Likely Candidates for Prefilled Syringes
Table 8.5 Vaccines: Likely Candidates for Prefilled Syringes
Table 9.1 Key Manufacturers of Prefilled Syringes
Table 9.2 West Pharmaceutical Services: Features of Daikyo Crystal Zenith® Prefilled Syringe
Table 9.3 Gerresheimer: Features of Gx® Glass Prefilled Syringe
Table 9.4 Gerresheimer: Features of ClearJect® Prefilled Syringe
Table 9.5 Nuova Ompi: Features of EZ-Fill® Prefilled Syringe
Table 9.6 SCHOTT: Features of syriQ® Prefilled Syringe
Table 9.7 SCHOTT: Features of syriQ® Injentle Prefilled Syringe
Table 9.8 SCHOTT: Features of TopPac® Prefilled Syringe
Table 9.9 Vetter Pharma: Manufacturing Facilities
Table 9.10 Weigao: Features of WeGo Glass Prefilled Syringe
Table 9.11 Roselabs Group: Features of Rose-Fill® Glass Prefilled Syringe
Table 9.12 Roselabs Group: Features of Rose-Fill® Plastic Prefilled Syringe
Table 9.13 Shandong Zibo: Features of Prefilled Syringes
Table 9.14 Taisei Kako: Features of Glass Prefilled Syringes
Table 9.15 Taisei Kako: Features of ClearJect®Prefilled Syringes
Table 10.1 Prefilled Syringe Component Manufacturers
Table 10.2 West Pharmaceutical Services: Plungers
Table 10.3 West Pharmaceutical Services: Manufacturing Sites for Prefilled Syringe Components
Table 10.4 Datwyler: Plunger Designs
Table 10.5 Datwyler: Needle Shields and Tip Caps
Table 10.6 Aptar Stelmi: Plungers Designs
Table 11.1 Fill-Finish Service Providers for Prefilled syringes
Table 11.2 Pfizer CentreOne: Manufacturing Plants
Table 11.3 ROVI CM: Manufacturing Plants
Table 12.1 Prefilled Flush Syringes Available in the Market
Table 12.2 Drugs Available in Prefilled Diluent Syringe System
Table 12.3 Contrast Agents Available in Prefilled Syringes
Table 13.1 Prefilled Syringes Price Estimate (USD per unit)
Table 13.2 Vaccines Administered via Prefilled Syringes
Table 13.3 List of Anticoagulants and Mode of Delivery
Table 13.4 List of Anticoagulants Sold in Prefilled Syringes
Table 13.5 List of Multiple Sclerosis Drugs and Mode of Delivery
Table 13.6 List of Multiple Sclerosis Drugs Sold in Prefilled Syringes
Table 13.7 List of Anti-Arthritic Drugs and Mode of Delivery
Table 13.8 List of Anti-Arthritic Drugs Sold in Prefilled Syringes
Table 13.9 List of Anti-Anemic Drugs and Modes of Drug Delivery
Table 13.10 List of Anti-Anemic Drugs Sold in Prefilled Syringes
Table 13.11 List of Other Drugs Sold in Prefilled Syringes
Table 13.12 List of Marketed Drugs in Prefilled Syringes
Table 13.13 List of Pipeline Drugs in Prefilled syringes (Phase III and Above)
Table 14.1 List of Autoinjector Devices (Using Prefilled Syringes)
Table 14.2 Features of Autoject® Flex Variants
Table 15.1 Prefilled Syringes for Lyophilized Drugs
Table 15.2 Drugs Marketed in Dual / Multi-Chamber Prefilled Syringes
Table 16.1 Prefilled Syringe Recalls, 2003-2016
Table 16.2 List of Marketed/Pipeline Needleless Injection Devices
Table 19.1 Global Prevalence of Diabetes: Distribution by Countries, 2015
(Million, %)
Table 19.2 Numbers of Biologics Approved by the USFDA, 2009-2016
Table 19.3 Approved Drugs: Therapeutic Area Analysis (2013-2016)
Table 19.4 Sales of Leading Drugs Available in Prefilled Syringes, 2016 (USD Million)
Table 19.5 HUMIRA®: Global Sales, 2003-Q3 2016 (USD Million)
Table 19.6 Enbrel®: Annual Sales in the US and Canada, 2002-2015 (USD Million)
Table 19.7 Enbrel®: Annual Sales Outside US and Canada, 2010-2015 (USD Million)
Table 19.8 Copaxone ®: Annual Sales, 2001-Q3 2016 (USD Million)
Table 19.9 Copaxone ®: Distribution by Vials and Prefilled Syringes, 2000-2008 (Million Units)
Table 19.10 Lovenox®: Global Annual Sales, 2009-Q3 2016 (EUR Million)
Table 19.11 Number of Approved / Pipeline Biosimilars of Anti-Rheumatics
Table 19.12 Number of Approved / Pipeline Biosimilars of Multiple Sclerosis Drugs
Table 19.13 Number of Approved / Pipeline Biosimilars of Antivirals
Table 19.14 Number of Approved / Pipeline Biosimilars and Generics of Anticoagulants
Table 19.15 Number of Approved / Pipeline Biosimilars of Diabetes Drugs
Table 19.16 BD Medical: Annual Revenues, 2011-2016 (USD Billion)
Table 19.17 BD Medical: Revenue Distribution by Sub-Segments, 2016 (USD Billion)
Table 19.18 Unilife Corporation: Annual Revenues, FY 2011/12-2015/16 (USD Million)
Table 19.19 West Pharmaceutical Services: Annual Revenues, 2011-Q3 2016 (USD Million)
Table 19.20 West Pharmaceutical Services: Revenue Distribution by Business Segments, 2015 (USD Million)
Table 19.21 West Pharmaceutical Services: Annual Revenues of Delivery Systems Segment, 2011-2015 (USD Million)
Table 19.22 West Pharmaceutical Services: Annual Revenue in the US and Overseas, 2011-2015 (USD Million)
Table 19.23 West Pharmaceutical Services: Revenue Distribution by Region, 2015 (USD Million)
Table 19.24 Gerresheimer: Annual Revenues, 2011-Q3 2016 (EUR Million)
Table 19.25 Gerresheimer: Revenue Distribution by Business Divisions, 2015 (EUR Million)
Table 19.26 Gerresheimer: Revenue Distribution by Regions, 2011- 2015 (EUR Million)
Table 19.27 SCHOTT: Annual Revenues, FY 2012/13-FY 2014/15 (EUR Million)
Table 19.28 SCHOTT: Revenue Distribution by Business Divisions, FY 2014/15 (EUR Million)
Table 19.29 SCHOTT: Revenue Distribution by Regions, FY 2014/15 (EUR Million)
Table 19.30 Nipro Corporation: Annual Revenues, 2011/12-2015/16 (YEN Billion)
Table 19.31 Nipro Corporation: Revenue Distribution by Business Divisions, 2015/16 (YEN Billion)
Table 19.32 Nipro Corporation: Revenue Distribution by Regions, 2015/16 (YEN Billion)
Table 19.33 Nipro Corporation: Revenue by Regions, 2011/12-2015/16 (YEN Billion)
Table 19.34 Weigao: Annual Revenues of Prefilled Syringes, 2011-H1 2016 (RMB Million)
Table 19.35 Weigao: Revenue Distribution by Product Category, 2015 (RMB Million)
Table 19.36 Terumo Corporation: Annual Revenues, 2011-H1 2016 (YEN Billion)
Table 19.37 Terumo Corporation: Revenue Distribution by Business Divisions, FY 2015/16 (YEN Billion)
Table 19.38 Terumo Corporation: Revenue Distribution by Region, FY 2015/16 (YEN Billion)
Table 19.39 Datwyler Group: Annual Revenues, 2011-H1 2016 (CHF Million)
Table 19.40 Datwyler Group: Sales by Business Divisions, 2015 (CHF Million)
Table 19.41 Aptar Stelmi: Annual Revenues, 2013-2015 (USD Million)
Table 19.42 Prefilled Syringes Price Curve, 2016-2026 (USD per unit)
Table 19.43 Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (Million Units)
Table 19.44 Prefilled Syringes Market for Vaccines, 2016-2026: Optimistic Scenario (Million Units)
Table 19.45 Prefilled Syringes Market for Vaccines, 2016-2026: Conservative Scenario (Million Units)
Table 19.46 Prefilled Syringes Market for Vaccines, 2016-2026: Base Scenario (USD Million)
Table 19.47 Prefilled Syringes Market for Vaccines, 2016-2026: Optimistic Scenario (USD Million)
Table 19.48 Prefilled Syringes Market for Vaccines, 2016-2026: Conservative Scenario (USD Million)
Table 19.49 Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (Million Units)
Table 19.50 Prefilled Syringes Market for Anticoagulants, 2016-2026: Optimistic Scenario (Million Units)
Table 19.51 Prefilled Syringes Market for Anticoagulants, 2016-2026: Conservative Scenario (Million Units)
Table 19.52 Prefilled Syringes Market for Anticoagulants, 2016-2026: Base Scenario (USD Million)
Table 19.53 Prefilled Syringes Market for Anticoagulants, 2016-2026: Optimistic Scenario (USD Million)
Table 19.54 Prefilled Syringes Market for Anticoagulants, 2016-2026: Conservative Scenario (USD Million)
Table 19.55 Prefilled Syringes Market for Anticoagulants, 2016: Distribution by Nature of Molecule (%)
Table 19.56 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (Million Units)
Table 19.57 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Optimistic Scenario (Million Units)
Table 19.58 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Conservative Scenario (Million Units)
Table 19.59 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Base Scenario (USD Million)
Table 19.60 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Optimistic Scenario (USD Million)
Table 19.61 Prefilled Syringes Market for Diabetes Drugs, 2016-2026: Conservative Scenario (USD Million)
Table 19.62 Prefilled Syringes Market for Diabetes Drugs, 2016: Distribution by Nature of Molecule (%)
Table 19.62 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (Million Units)
Table 19.63 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Optimistic Scenario (Million Units)
Table 19.64 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Conservative Scenario (Million Units)
Table 19.65 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Base Scenario (USD Million)
Table 19.66 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Optimistic Scenario (USD Million)
Table 19.67 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016-2026: Conservative Scenario (USD Million)
Table 19.68 Prefilled Syringes Market for Multiple Sclerosis Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
Table 19.69 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (Million Units)
Table 19.70 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Optimistic Scenario (Million Units)
Table 19.71 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Conservative Scenario (Million Units)
Table 19.72 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Base Scenario (USD Million)
Table 19.73 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Optimistic Scenario (USD Million)
Table 19.74 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016-2026: Conservative Scenario (USD Million)
Table 19.75 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016 and 2026: Distribution by Nature of Molecule (%)
Table 19.76 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (Million Units)
Table 19.77 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Optimistic Scenario (Million Units)
Table 19.78 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Conservative Scenario (Million Units)
Table 19.79 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Base Scenario (USD Million)
Table 19.80 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Optimistic Scenario (USD Million)
Table 19.81 Prefilled Syringes Market for Anti-Anemic Drugs, 2016-2026: Conservative Scenario (USD Million)
Table 19.82 Prefilled Syringes Market for Anti-Arthritic Drugs, 2016: Distribution by Nature of Molecule (%)
Table 19.83 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (Million Units)
Table 19.84 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Optimistic Scenario (Million Units)
Table 19.85 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Conservative Scenario (Million Units)
Table 19.86 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Base Scenario (USD Million)
Table 19.87 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Optimistic Scenario (USD Million)
Table 19.88 Prefilled Syringes Market for Other Drug Classes, 2016-2026: Conservative Scenario (USD Million)
Table 19.89 Prefilled Syringes Market for Other Drug Classes, 2016 and 2026: Distribution by Nature of Molecule (%)
Table 19.90 Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (Millions Units)
Table 19.91 Specialty Prefilled Syringes Market, 2016-2026: Optimistic Scenario (Millions Units)
Table 19.92 Specialty Prefilled Syringes Market, 2016-2026: Conservative Scenario (Millions Units)
Table 19.93 Specialty Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Table 19.94 Specialty Prefilled Syringes Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.95 Specialty Prefilled Syringes Market, 2016-2026: Conservative Scenario (USD Million)
Table 19.96 Global Prefilled Syringes Market, 2016-2026: Base Scenario (Million Units)
Table 19.97 Global Prefilled Syringes Market, 2016-2026: Optimistic Scenario (Million Units)
Table 19.98 Global Prefilled Syringes Market, 2016-2026: Conservative Scenario (Million Units)
Table 19.99 Global Prefilled Syringes, Units Growth by Category, 2016- 026 (Base Scenario, Million Units)
Table 19.100 Global Prefilled Syringes, Units Growth by Category, 2016 - 2026 (Optimistic Scenario, Million Units)
Table 19.101 Global Prefilled Syringes, Units Growth by Category, 2016 - 2026 (Conservative Scenario, Million Units)
Table 19.102 Global Prefilled Syringes Market, 2016-2026: Base Scenario (USD Million)
Table 19.103 Global Prefilled Syringes Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.104 Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Conservative Scenario, USD Million)
Table 19.105 Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Base Scenario, USD Million)
Table 19.106 Global Prefilled Syringes, Sales Growth by Category, 2016-2026 (Optimistic Scenario, USD Million)
Table 19.107 Global Prefilled Syringes, Sales Growth by Category, 2016 - 2026 (Conservative Scenario, USD Million)
Table 19.108 Prefilled Syringe Market: Distribution by Regions, 2016 and 2026 (%)
Table 19.109 North America Prefilled Syringe Market, 2016-2026: Base Scenario (Million Units)
Table 19.110 North America Prefilled Syringe Market, 2016-2026: Optimistic Scenario (Million Units)
Table 19.111 North America Prefilled Syringe Market, 2016-2026: Conservative Scenario (Million Units)
Table 19.112 North America Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
Table 19.113 North America Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.114 North America Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
Table 19.115 EU Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Table 19.116 EU Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Optimistic Scenario (Million Units)
Table 19.117 EU Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Conservative Scenario (Million Units)
Table 19.118 EU Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
Table 19.119 EU Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.120 EU Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
Table 19.121 Asia Pacific Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Table 19.122 Asia Pacific Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Optimistic Scenario (Million Units)
Table 19.123 Asia Pacific Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Conservative Scenario (Million Units)
Table 19.124 Asia Pacific Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
Table 19.125 Asia Pacific Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.126 Asia Pacific Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
Table 19.127 Latin America Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Table 19.128 Latin America Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Optimistic Scenario (Million Units)
Table 19.129 Latin America Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Conservative Scenario (Million Units)
Table 19.130 Latin America Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
Table 19.131 Latin America Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.132 Latin America Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
Table 19.133 Middle East and Africa Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Base Scenario (Million Units)
Table 19.134 Middle East and Africa Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Optimistic Scenario (Million Units)
Table 19.135 Middle East and Africa Prefilled Syringe Market, 2016-2026: Distribution by Sub-Regions, Conservative Scenario (Million Units)
Table 19.136 Middle East and Africa Prefilled Syringe Market, 2016-2026: Base Scenario (USD Million)
Table 19.137 Middle East and Africa Prefilled Syringe Market, 2016-2026: Optimistic Scenario (USD Million)
Table 19.138 Middle East and Africa Prefilled Syringe Market, 2016-2026: Conservative Scenario (USD Million)
Table 19.39 Prefilled Syringe Market Attractiveness Analysis by Region
Table 19.140 Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Base Scenario (Million Units)
Table 19.141 Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Optimistic Scenario (Million Units)
Table 19.142 Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Conservative Scenario (Million Units)
Table 19.143 Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Base Scenario (USD Million)
Table 19.144 Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Optimistic Scenario (USD Million)
Table 19.145 Prefilled Syringe Market, 2016-2026: Distribution by Type of Material, Conservative Scenario (USD Million)
Table 19.146 Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (Million Units)
Table 19.147 Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Optimistic Scenario (Million Units)
Table 19.148 Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Conservative Scenario (Million Units)
Table 19.149 Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Base Scenario (USD Million)
Table 19.150 Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Optimistic Scenario (USD Million)
Table 19.151 Prefilled Syringe Market, 2016-2026: Distribution by Nature of Molecule, Conservative Scenario (USD Million)
Table 19.152 Prefilled Syringe Market Attractiveness Analysis by Nature of Molecules
Table 19.153 Common Medication Errors
Table 19.154 Common Sources of Medication Errors
Table 19.155 Prefilled Syringe Recalls: Distribution by Type of Issue, 2003-2016
Table 19.156 Prefilled Syringes Market: 2016, 2021 and 2026 (Billion Units)
Table 19.157 Prefilled Syringes Market: 2016, 2021, and 2026 (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report